Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | LIG1 | P18858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441058 | 1.00 | TDP1 (0.44) | TDP1CYP19A1MGLLHDAC3HDAC1 | |
| SCHEMBL28983076 | 1.00 | TDP1 (0.44) | TDP1CYP19A1MGLLHDAC3HDAC1 | |
| SCHEMBL28983077 | 0.83 | DGAT1 (0.48) | KMT2ASMN1; SMN2TSHRKDM1AMAOB | |
| SCHEMBL28983075 | 0.83 | DGAT1 (0.48) | KMT2ASMN1; SMN2TSHRKDM1AMAOB | |
| SCHEMBL30712600 | 0.82 | TDP1 (0.42) | TDP1CYP19A1MGLLGSK3BBACE1 | |
| SCHEMBL30712573 | 0.82 | TDP1 (0.42) | TDP1CYP19A1MGLLGSK3BBACE1 | |
| SCHEMBL23632413 | 0.81 | DGAT1 (0.34) | — | |
| SCHEMBL3650274 | 0.81 | ESR2 (0.42) | TDP1CYP19A1HDAC3HDAC1HDAC2 | |
| SCHEMBL3650278 | 0.81 | ESR2 (0.42) | TDP1CYP19A1HDAC3HDAC1HDAC2 | |
| SCHEMBL5663809 | 0.81 | CYP19A1 (0.40) | TDP1CYP19A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115927276-A | Halogen alcohol dehalogenase mutant and application thereof in synthesizing chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2023-04-07 | — | — | CN | claimed |
| EP-4553069-A1 | ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790041-A | Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-04-08 | — | — | CN | disclosed |
| CN-117466833-A | Chiral 2-oxazolidinone and asymmetric synthesis method thereof | 三峡大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-117402123-A | Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-01-16 | — | — | CN | disclosed |
| WO-2024008166-A1 | α,β-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2024-01-11 | — | — | WO | disclosed |
| CN-112204018-B | Acrylic compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-08-29 | — | — | CN | disclosed |
| CN-115927276-A | Halogen alcohol dehalogenase mutant and application thereof in synthesizing chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2023-04-07 | — | — | CN | disclosed |
| CN-112204018-A | Acrylic acid compounds, preparation method thereof, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2021-01-08 | — | — | CN | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | MC2R, AGTR2, AGTR1 | TDP1 3523/4885CYP19A1 2042/4885MGLL 3647/4885 |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | TDP1 2171/4885CYP19A1 659/4885MGLL 4877/4885 |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | MC2R, CNR1, NPY2R | TDP1 3567/4885CYP19A1 1837/4885MGLL 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.